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Primary  cutaneous  T-cell  lymphomas  (CTCLs),  such  as  mycosis  fungoides  and  Sézary  syndrome,  are  a rare
group  of non-Hodgkin  lymphomas,  usually  treated  using  a  multimodal  approach.  Unfortunately,  many
patients  go  on  to develop  relapsed/refractory  disease.  Systemic  treatment  for relapsed/refractory  CTCL
has historically  relied  on  chemotherapies  and  interferons,  and  while  active,  responses  are  often  short-
lived.  Three  drugs  are  now  approved  in  the  US  to treat relapsed/refractory  CTCL  including  the  oral  retinoid,
bexarotene,  and  histone  deacetylase  inhibitors,  romidepsin  and  vorinostat.  Although  response  rates  are
typically  <35%,  romidepsin  and  vorinostat  can  induce  some  durable  responses  in heavily  pretreatedrentuximab vedotin
utaneous T-cell lymphoma
ycosis fungoides
omidepsin
ézary syndrome
orinostat
patients  and  alleviate  bothersome  symptoms,  such  as pruritus.  New  studies  indicate  that  the anti-CD30
antibody-drug  conjugate  brentuximab  vedotin,  anti-CCR4  antibody  mogamulizumab,  and  fusion  pro-
tein  immunotoxin  A-dmDT390-bisFv(UCHT1)  may  be  particularly  active  in this  setting.  In  this  paper,  we
present  an  exhaustive  review  of the  clinical  data  on current  and  possible  future  drug  treatment  options
for relapsed/refractory  CTCL.
©  2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC∗ Corresponding author. Fax: +39 516364037.
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040-8428/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open
icenses/by-nc-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Primary cutaneous T-cell lymphomas (CTCLs) are a rare group
of non-Hodgkin lymphomas (NHLs) derived from malignant trans-
formation of mature skin-homing/resident T cells (Guenova et al.,
2014). They represent a disparate group of lymphoid T-cell
 access article under the CC BY-NC-ND license (http://creativecommons.org/
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alignancies with heterogeneous clinical, immunologic, histologic,
ytogenetic, and molecular characteristics. CTCLs are less common
han peripheral T-cell lymphomas (PTCLs) and only account for
bout 4% of all NHLs (Criscione and Weinstock, 2007). The annual
ge-adjusted incidence of CTCLs in the United States is about 6–10
er million persons (Criscione and Weinstock, 2007; Imam et al.,
013; Korgavkar et al., 2013). While the incidence of CTCLs has
emained stable since 1998 in the United States, it is increasing
n some Asian countries, such as Japan (Korgavkar et al., 2013;
hihara et al., 2014); this is believed to be due to the adoption of a
ore westernized lifestyle (Chihara et al., 2014). CTCLs are approx-
mately twice as common in men  than in women, with black men
articularly affected (Criscione and Weinstock, 2007; Imam et al.,
013; Bradford et al., 2009; Wilson et al., 2012). Usually diagnosed
n patients aged 50–70 years, the prevalence of CTCL (all subtypes
nd stages combined) peaks between the ages of 70 and 84 years
Criscione and Weinstock, 2007; Korgavkar et al., 2013; van Doorn
t al., 2000; Kim et al., 2003).
The most common CTCL subtype is mycosis fungoides (MF)
Criscione and Weinstock, 2007), which together with its more
ggressive leukemic and erythrodermic variant, Sézary syndrome
SS), accounts for about 65% of all CTCLs (Guenova et al., 2014;
rautinger et al., 2006). Other CTCL subtypes include primary
utaneous CD30+ TCL (primary cutaneous ALCL [pcALCL] and lym-
homatoid papulosis [LyP], which represent at least 25% of all CTCLs
Willemze et al., 2005)) and rarer entities, such as primary cuta-
eous gamma/delta type TCL, primary cutaneous CD8+ aggressive
pidermotropic TCL, and primary cutaneous CD4+ small/medium
CL (Fig. 1). The aggressiveness of CTCL depends on the diagno-
is: MF,  primary cutaneous CD30+ TCL (pcALCL/LyP), and primary
utaneous CD4+ small/medium TCL tend to run a rather indolent
ourse, whereas SS and other rare primary cutaneous TCL entities
re often associated with rapid progression and low survival rates
Swerdlow et al., 2008; Li et al., 2012). Five-year survival rates vary
rom 25 to 40% in SS to 73–100% in MF  or primary cutaneous CD30+
CL (MF  88–91%, LyP 73–100%, and pcALCL 95–96%) (Bradford et al.,
009; Willemze et al., 2005; Bekkenk et al., 2000).
CTCLs are generally treated using a multimodal approach,
lthough there is no single common management plan (espe-
ially for the rarer variants) due to the diversity of diagnoses and
linical presentations. Frontline treatment for limited disease is
sually directed at the lesion, and involves using a combination
f surgery, radio- and phototherapy, and speciﬁc skin-directed
reatments (topical corticosteroids, chemotherapies, retinoids, or
miquimod) (National Cancer Institute, 2015; Akilov and Geskin,
011). Systemic therapies and autologous or allogeneic stem cell
ransplantation tend to be reserved as options for more general-
zed or advanced disease (e.g., for patients with folliculotropic or
arge-cell transformation, or blood/organ involvement) (National
ancer Institute, 2015; Akilov and Geskin, 2011). The most indo-
ent variants of CTCL, including pcALCL, LyP, and primary cutaneous
D4+ small/medium TCL, which are associated with excellent prog-
oses, often require less aggressive treatment, although treatment
s not curative (National Cancer Institute, 2015; James et al., 2015;
empf et al., 2011). Localized or solitary pcALCL, for instance, can be
reated with surgical excision and/or radiotherapy if spontaneous
emission does not occur, with systemic therapies reserved for the
mall minority of patients with multifocal lesions/extracutaneous
issemination (National Cancer Institute, 2015; Kempf et al., 2011).
rimary cutaneous CD4+ small/medium TCL is often treated in
 similar manner despite the lack of a standardized treatment
pproach (James et al., 2015). For LyP, which is characterized by
hronic, recurrent, spontaneously regressing, papulonodular skin
esions, observation alone (in asymptomatic patients with few
esions and minimal scarring), topical treatments, or phototherapy
ay  be sufﬁcient for most patients (National Cancer Institute, 2015;ogy/Hematology 99 (2016) 228–240 229
Kempf et al., 2011). Regrettably, however, many patients with
CTCL who  receive frontline therapy, particularly those with the
more aggressive subtypes, will relapse and/or develop treatment-
refractory disease (Dreyling et al., 2013).
Until recently, treatment for relapsed/refractory CTCL had been
very challenging due to the limited options available; however,
the introduction of new treatments is beginning to have a positive
impact on clinical outcomes. In this article, we present an exhaus-
tive review of the clinical data on current and possible future drug
treatment options for relapsed/refractory CTCL, looking at both
approved and investigational agents and regimens.
2. Review methodology
A literature search was conducted to identify studies reporting
clinical outcomes following drug therapy in patients with relapsed
and/or refractory CTCL (deﬁned according to the 2008 World Health
Organization classiﬁcation) (Fig. 1) (Swerdlow et al., 2008). MED-
LINE (PubMed) was searched for studies published up to February
6, 2015, and reference lists of recent reviews and meta-analyses
(2011–14) were investigated manually. Congress abstracts from the
American Society of Clinical Oncology (ASCO), American Society of
Hematology (ASH), European Society for Medical Oncology (ESMO),
and European Hematology Association (EHA) annual meetings
(2013–14) were also evaluated. Search terms included ‘cutaneous
T-cell lymphoma’, ‘mycosis fungoides’, ‘Sézary syndrome’, ‘primary
cutaneous CD30-positive T-cell lymphoma’, ‘primary cutaneous
anaplastic large cell lymphoma’, and ‘lymphomatoid papulosis’.
Results were screened by title and abstract to identify clinical
studies of pharmacologic therapies in relapsed and/or refractory
CTCLs. Prospective trials were selected as the primary data sources;
studies of previously untreated patients were excluded. After iden-
tifying relevant publications, data were collected on study type,
patients, diagnosis, treatment history, and efﬁcacy.
3. Treatment of relapsed/refractory CTCL
Treatments for relapsed/refractory CTCLs generally consist of
additional or alternative skin-directed therapies with or with-
out systemic biologic agents or chemotherapy (National Cancer
Institute, 2015; Willemze et al., 2013). Phototherapy, local radio-
therapy, total skin electron beam therapy, and extracorporeal
photopheresis are also sometimes used as adjunct options as part
of a multimodal treatment approach (National Cancer Institute,
2015). For the more indolent CTCLs, options for relapsed/refractory
disease are similar to frontline treatment (e.g., methotrexate,
chemotherapy, and radiotherapy) with participation in a clini-
cal trial as an additional option (Bekkenk et al., 2000; National
Cancer Institute, 2015; Kempf et al., 2011). The aim of treatment
in relapsed/refractory CTCL is to safely induce prolonged remission
without compromising a patient’s immunity or adversely affecting
their quality of life (Akilov and Geskin, 2011). As stated in Sec-
tion 2 (Review Methodology), the following review focuses only
on systemic drug therapies that have been investigated speciﬁcally
in relapsed/refractory CTCL, with an emphasis on novel therapies.
It is beyond the scope of this paper to discuss other treatment
approaches in CTCL.
As most recent trials in relapsed/refractory CTCL have recruited
patients with MF  or SS, the term ‘CTCL’ is often used synony-
mously with these two conditions in many published articles. It
is also important to note that cross-trial comparisons are prob-
lematic in this setting because of differences in: (1) the tools used
to measure objective responses, which may  not always consider
nodal, blood, and visceral involvement, in addition to the ubiqui-
tous assessment of cutaneous manifestations; (2) the criteria used
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naplastic lymphoma kinase; EBV, Epstein-Barr virus; LPD, lymphoproliferative dis
o diagnose and classify patients; and (3) deﬁnitions of clinical end-
oints and follow-up times. All of these factors, in addition to the
xpected variations in study populations, need to be considered
hen comparing trial results.
.1. Conventional therapies in relapsed/refractory CTCL
A number of systemic chemotherapies have traditionally been
sed to treat patients with relapsed/refractory CTCL. As in PTCL,
he evidence for using such therapies is largely derived from retro-
pective cohort studies and case series, and only a small minority
f patients achieve durable responses.
In general, chemotherapy in relapsed/refractory CTCL is admin-
stered as monotherapy (National Cancer Institute, 2015), as
ulti-agent treatment can result in increased immunosuppres-
ion (resulting in an increased risk of serious infection) and poor
olerance (Akilov and Geskin, 2011). Examples of single-agent
hemotherapies that are used in relapsed/refractory CTCL include
emcitabine, pentostatin, temozolomide, methotrexate, ﬂudara-
ine, etoposide, cyclophosphamide, and chlorambucil (National
ancer Institute, 2015; Quereux et al., 2008). Of these therapies,
emcitabine, temozolomide, and pentostatin have been investi-
ated in prospective clinical trials (Duvic et al., 2006a; Tani et al.,
005; Querfeld et al., 2011; Cummings et al., 1991; Monfardini
t al., 1996; Kurzrock et al., 1999; Ho et al., 2000; Tsimberidou
t al., 2004), as well as in observational studies (Zinzani et al.,
000; Zinzani et al., 2010; Pellegrini et al., 2014; Jidar et al., 2009;
ercieca et al., 1994; Greiner et al., 1997; Foss, 2000; Dearden
t al., 2000). As shown in Table 1, these three cytotoxic agents can
nduce clinical responses in a substantial proportion of patients.
emcitabine appears to be one of the most effective single-agent
hemotherapies with overall response rates (ORRs) of 48–68%,
omplete response (CR) rates of 9–20%, and reports of some pro-
onged responses (albeit uncommon) (Duvic et al., 2006a; Zinzani
t al., 2000; Zinzani et al., 2010; Pellegrini et al., 2014; Jidar et al.,
009). The purine analog, pentostatin is also active (ORR 14–71%,
R rate 0–25%), and there is a suggestion that this agent maytaneous T-cell lymphomas (Swerdlow et al., 2008) +, positive; −, negative; ALK,
; TCL, T-cell lymphoma; NK, natural killer; NOS, not otherwise speciﬁed.
achieve particularly high response rates (up to 71%) in patients
with SS (Cummings et al., 1991; Monfardini et al., 1996; Kurzrock
et al., 1999; Ho et al., 2000; Tsimberidou et al., 2004; Mercieca
et al., 1994; Greiner et al., 1997). Although prospective studies are
lacking, methotrexate appears to be similarly active in previously
treated CTCL (Zackheim et al., 1996; Zackheim et al., 2003).
More recently, pegylated liposomal doxorubicin (PLD) – a for-
mulation of doxorubicin in polyethylene glycol-coated liposomes
that has a prolonged circulation time, higher target speciﬁcity, and
improved safety proﬁle compared with the parent drug (Gabizon,
2001) – has achieved impressive response rates (ORR 41–84%) in
relapsed/refractory CTCL patients, including those with advanced
MF or SS (Quereux et al., 2008; Wollina et al., 2003; Pulini et al.,
2007; Dummer et al., 2012; Straus et al., 2014). These results imply
that PLD is at least as active as other single-agent chemotherapies
in this setting. Treatment with PLD also appears to be generally
well tolerated, with a low rate of grade 3/4 adverse events (AEs)
(Quereux et al., 2008; Dummer et al., 2012; Wollina et al., 2000).
Toxicities associated with PLD reﬂect those seen with doxoru-
bicin (albeit at a lower severity), and include asthenia, fatigue,
fever, anorexia, nausea, vomiting, stomatitis, diarrhea, constipa-
tion, hand-foot syndrome, rash, neutropenia, thrombocytopenia,
and anemia (DOXIL®, 2015).
Interferons ( and ) also still have a role in the treatment of
relapsed/refractory CTCL (National Cancer Institute, 2015), but as
they have been used for many decades, it is beyond the scope of this
paper to report the clinical data on these agents. The effectiveness
and safety of interferons in CTCL is reviewed in detailed by Olsen
(Olsen, 2003).
3.2. Approved therapies in relapsed/refractory CTCL
Over the past 15 years, novel targeted agents have been intro-
duced into therapy for relapsed/refractory CTCL. Four of these
agents are currently approved for use in the United States for
the treatment of relapsed/refractory CTCL (Table 1). The ﬁrst of
these drugs is bexarotene, an orally administered retinoid that
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Table  1
Summary of prospective clinical trials for approved (bexarotene, denileukin diftitox, romidepsin, and vorinostat) and investigational/off-label agents and regimens in
relapsed/refractory cutaneous T-cell lymphoma.
Agent/regimen
and reference
Phase N CTCL
diagnoses
Median prior
treatments
(range)
ORR (%)a CR/CCR
rate
(%)a
Median DoR,
months
(range/95% CI)
Median PFS,
months
Median OS,
months
Pruritus
improvement
Bexarotene
Duvic et al.
(2001a)
2/3 94 CTCL n = 94 5 (1–11)
Sys: 2 (1–6)
45–55 2–13 9.8–12.7b NR NR Y
Duvic et al.
(2001b)
2/3 58 CTCL n = 58 3 (2–8) 54–67 7–27 NR–14.9 6.9–16.9c NR Y
Bexarotene + denileukin diftitox
Foss et al.
(2005)
1 12 CTCL n = 14 NR (1–12) 67 33 NR NR NR NR
Bexarotene + gemcitabine
Illdge et al.
(2013)
2 36 CTCL n = 35
Erythro
n = 17
NR 31 Erythro: 18
non-Erythro:
42
0 NR 5.3 Erythro:
5.3
non-Erythro:
4.6
21.2 Y
Bexarotene + IFN
Straus et al.
(2007)
2 18 CTCL n = 18 NR 39d 6d 2.7 (1.1–7.6)d NR NR NR
Bexarotene + pralatrexate
Talpur et al.
(2014)
1/2 14 MF n = 14 NR 50 0 NR NR NR NR
Denileukin diftitox
LeMaistre et al.
(1998)
1 35 CTCL n = 35 3 (0–15) 37 14 10 (2.4–39+)e NR NR NR
Saleh et al.
(1998)
1 35 IL-2R+: MF
n = 30
pcALCL
n = 4 Other
CTCL n = 1
3 (0–6)d 37d 14d NR NR NR Y
Olsen et al.
(2001)
3 71 MF or SS
n  = 71
5 (1–12) 30 10 6.9 (2.7–46.1+) NR NR Y
Prince et al.
(2010)
3 144 All CD25+:
MF n = 123
SS n = 9
Other
n = 12
NR (0–3+) 44f (central) 10f 7.8+ 26.1+ NR Y
Prince et al.
(2013)
4 36 ALL CD25–:
MF  or SS
n  = 36
NR 31 (central) 8 11.2 (4.6, not
reached)
16.0+ NR Y
Duvic et al.
(2013a)g
3 20 MF n = 20 NR 40 10 9.0 6.7 NR Y
Duvic et al.
(2013b)
Pooled phase 3
3 263 CTCL
n = 263
NR 38
9 g/kg:
3118 g/kg: 47
Retreated: 28
CD25–: 31
9 9.1 (1.4–43.5)
9 g/kg: 9.1
18 g/kg: 8.8
Retreated: 9.0
CD25–: 11.2
NR NR NR
Talpur and
Duvic (2012)
Pilot 8 CD30+
cALCL = 5
Other
pcPTCL
n = 3
NR (1–2) 62.5 25 2.8 (1.8–95.7) NR NR NR
Romidepsin
Piekarz et al.
(2009)
2 71 MF or SS
n  = 71
4 (0–14) 34 7 13.7 NR
responders:
15.1c
NR NR
Whittaker et al.
(2010) and
Duvic et al.
(2014a)
2 96 CTCL n = 96 4 (1–11) Sys: 3
(1–8)
34 Prior CT: 34 6 Prior
CT: 8
15.0 (0+–19.8+)
prior CT: 15
8c NR Y
Vorinostat
Olsen et al.
(2007)
2b 74 MF n = 44
SS n = 30
Sys: 3 (1–12) 30 SS: 33 1 ≥6.1
(1.1 + –14.5 + )
≥4.9c NR Y
Duvic et al.
(2007)
2 33 MF n = 22
SS n = 11
Sys: 5 (1–15) 24 SS: 36 0 3.5 (2.2–4.5) 2.8c NR Y
Wada et al.
(2012)
1 6 MF n = 6 Sys: 2.5 (1–5) 0 0 NR NR NR Y
Alemtuzumab
Kennedy et al.
(2003)
2 8 MF n = 5 SS
n  = 2 tMF
n = 1
NR (1–17) 38 0 NR (1.8–3.2) 2.2c 4 Y
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Table 1 (Continued)
Agent/regimen
and reference
Phase N CTCL
diagnoses
Median prior
treatments
(range)
ORR (%)a CR/CCR
rate
(%)a
Median DoR,
months
(range/95% CI)
Median PFS,
months
Median OS,
months
Pruritus
improvement
Lundin et al.
(2003)
2 22 CD52+ MF
or SS n = 22
3 (1–5) 55 32 NR NR NR Y
Zinzani et al.
(2005)
2 4 MF  n = 4 3 (2–4)h 75 0 7 (2–10)h NR NR NR
Bernengo et al.
(2007)
NR 11 SS n = 11 86i 21i Not reached NR 35i Y
Querfeld et al.
(2009)
2 19 Erythro MF
n = 2 SS
n = 17
5 (2–10) Sys: 3
(1–7) Skin: 1
(1–5)
84 47 6 (2–39+) 6 41 NR
Belinostat
Foss et al.
(2015)
2 29 MF  n = 17
SS n = 7
pcALCL
n = 2 other
CTCL n = 2
SPTCL n = 1
NR (1–12)
Sys: 4 (1–9)
Skin: 1 (0–4)
14 10 2.7 (1.8, 4.2) 1.4c NR Y
Bortezomib
Zinzani et al.
(2007)
2 12 MF  n = 10
pcPTCL
n = 2
NR (2–5) 67
MF: 70
17
MF:  10
NR NR NR NR
Brentuximab vedotin
Duvic et al.
(2015a)
2 48 CD30+: MF
n = 28 LyP
n = 9
pcALCL
n = 2
LyP/MF
n = 7
pcALCL/LyP/MF
n = 2
5 (1–13) 73 MF:  54 LyP:
100 pcALCL:
100 LyP/MF:
100
pcALCL/LyP/MF:
100
35 MF:
7 LyP:
56
pcALCL:
100
LyP/MF:
86
pcALCL/LyP/MF:
100
NR MF:  7.4
(0.7–21.5)
LyP/pcALCL:
6.0 (1.4–10.2)
13.2 Not reached NR
Kim et al. (2015) 2 32 CD30,
0–100%
(median
13%):
MF  stage
IB/IIB n = 22
MF stage
IV/SS n = 10
3 (1–13) 70 MF  stage
IB/IIB: 77 MF
stage IV/SS: 50
CD30 <10%: 54
CD30 10–50%:
79 CD30 >50%:
100
3 NR (1-yr: 79%) NR (1-yr:
54%)
NR NR
Duvelisib (IPI-145)
Horwitz et al.
(2014)
1 17 CTCL n = 17 4 (1–11)j 38 0 NR NR Not reached NR
E7777
Duvic et al.
(2014b)
3 17 MF  n = 13
SS n = 4
NR (≥4: 82%) 29 6 NR NR NR NR
Forodesine
Duvic et al.
(2006b)
1/2 37 CTCL n = 37 NR 54 7 NR NR NR NR
Duvic et al.
(2009a)
NR 64 CTCL n = 64 NR 27 NR NR NR NR NR
Dummer et al.
(2014)
2 144 MF  n = 125
SS n = 19
4 (3–15) 11 0 6.3 6.3c NR NR
Gemcitabine
Duvic et al.
(2006a)
2 33 CD30+
cALCL n = 2
MF  or SS
n  = 31
5 (1–13) 64 MF:  54 SS:
73
9 NR NR 20.4 (3 yr:
24%)
NR
Lenalidomide
Querfeld et al.
(2014)
2 32 MF  n = 18
Erythro MF
n = 3 SS
n = 11
6 (1–14) Sys: 4
(0–12) Skin: 2
(0–6)
28 Erythro
MF/SS: 38
0 10 (1.1, 11.0) 8 43 (1 yr:
83%, 2 yr:
62%, 5 yr:
48%)
NR
Mogamulizumab
Ogura et al.
(2014)
2 8 CCR4+: MF
n = 7 cALCL
n = 1
3 (1–6) 38 MF:  29
cALCL: 100
0 NR NR NR NR
Duvic et al.
(2015b)
1/2 41 MF  n = 22
SS n = 19
Sys: 3 (1–17) 37 MF:  47 SS:
29
8 MF: 5
SS: 12
10.4 (IQR
6.9–33.2)
11.4 NR NR
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Table  1 (Continued)
Agent/regimen
and reference
Phase N CTCL
diagnoses
Median prior
treatments
(range)
ORR (%)a CR/CCR
rate
(%)a
Median DoR,
months
(range/95% CI)
Median PFS,
months
Median OS,
months
Pruritus
improvement
Panobinostat
Ellis et al. (2008) 1 10 MF n = 7 SS
n  = 3
NR 60 20 NR 5.9c NR NR
Duvic et al.
(2013c)
2 139 MF n = 105
SS n = 33
Other n = 1
4 (1–15) 17 Bexarotene
exp: 15
Bexarotene
naïve: 20
2
Bexarotene
exp: 1
Bexarotene
naïve:
1
Bexarotene
exp: 5.6
Bexarotene
naïve: not
reached
Bexarotene
exp: 4.2
Bexarotene
naïve: 3.7
NR Y
Pentostatin
Cummings et al.
(1991)
2 8 CTCL n = 8 NR 50 NR NR NR NR NR
Monfardini
et al. (1996)
2 7 MF n = 5 SS
n  = 1 other
n = 1
NR 14 0 NR NR NR NR
Kurzrock et al.
(1999)
NR 24 SS n = 14
MF n = 6
tMF  n = 1
pcPTCL
n  = 3
3 (1–12) 71 SS: 71 MF:
66 pcPTCL: 100
25 NR MF:  2 (1–2)
SS: 3.5
NR NR NR
Ho et al. (2000) 2 43 MF n = 22
SS n = 21
NR SS: 33 MF:  23 SS: 5
MF:  0
NR NR SS: 8 MF:
12.5
NR
Tsimberidou
et al. (2004)
2 32 MF or SS
n  = 32
2 (1–12)k 56 13 NR NR 418k(2 year:
42%)k
NR
PLD
Wollina et al.
(2003)
Pilot 10 MF n = 6 NR 83 67 NR NR NR NR
Quereux et al.
(2008)
NR 25 MF n = 15
SS n = 10
NR (1–6) 56
SS: 60
20
SS: 10
NR NR
responders: 5
43.7 NR
Pulini et al.
(2007)
2 19 MF n = 10
tMF  n = 3 SS
n = 3
pcPTCL
n = 3
NR (1–5) 84 42 NR 19
(46 mo: 37%)
34
(46 mo:
44%)
NR
Dummer et al.
(2012)
2 49 MF n = 49 NR 41 6 6 (5.0, 10.4) 7.4c NR NR
Straus et al.
(2014)
2 34 MF n = 27
SS n = 8
Other n = 2
2 (1–11) 41 SS: 50 6 NR NR NR Y
Pralatrexate
Horwitz et al.
(2012)
1/2 54 MF n = 38
SS n = 15
pcALCL
n = 1
6.5 (1–25)
Sys: 4 (1–11)
41 At OD: 45
MF:  47 SS: 20
6 At
OD: 3
MF:  3
SS: 7
At OD: not
reached
(0.03–12.2)
At OD: not
reached
NR NR
Resimmune
Frankel et al.
(2013)
1 17 CTCL n = 17 NR (0–4)l 35l 24l NR NR NR NR
Temozolomide
Tani et al.
(2005)
2 9 MF n = 9 3 (2–5) 33 11 NR NR NR NR
Querfeld et al.
(2011)
2 26 MF or SS
n  = 26
NR 27 8 NR 4 24
(1 yr: 86%, 2
yr: 50%, 5
yr: 25%)
NR
a Responses were measured using various assessment criteria.
b Median time to relapse.
c Time to progression.
d Includes data on 1 treatment-naïve patient.
e Data presented for CTCL (n = 13) and NHL (n = 3) patients.
f Includes data on 20 treatment-naïve patients.
g All patients had relapsed after responding to denileukin diftitox.
h Data presented for 10 patients: 4 with MF  and 6 with PTCL.
i Data presented for 14 SS patients: 11 relapsed/refractory and 3 newly diagnosed.
j Data presented for 33 patients: 17 with CTCL and 16 with PTCL.
k Data presented for 42 patients: 32 with MF/SS and 10 with PTCL.
l Includes data on 2 previously untreated patients. CCR, clinical complete response; central, central response review; CT, chemotherapy; CTCL, cutaneous T-cell lymphoma;
CR,  complete response; DoR, duration of response; Erythro, erythrodermic; IFN, interferon; IQR, inter-quartile range; LyP, lymphomatoid papilosis; MF,  mycosis fungoides;
NOS,  not otherwise speciﬁed; NR, not reported; OD, optimal dose; ORR, overall response rate; OS, overall survival; pcALCL, primary cutaneous anaplastic large cell lymphoma;
pcPTCL,  primary cutaneous peripheral T-cell lymphoma; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin; PTCL, peripheral T-cell lymphoma; PUVA,
psoralen plus ultraviolet A; SPTCL, subcutaneous, panniculitis-like T-cell lymphoma; SS, Sézary syndrome; Sys, systemic treatments; TCL, T-cell lymphoma; tMF, transformed
MF;  Y, yes.
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electively activates retinoid × receptors, which then act as tran-
cription factors to regulate the expression of genes that control
ellular proliferation and differentiation (Targretin®, 2015). In the
nited States, bexarotene is approved for the treatment of cuta-
eous manifestations of CTCL in patients who are refractory to at
east one prior systemic therapy (Targretin®, 2015). The second
pproved agent is romidepsin, an intravenously (IV) administered,
pigenetic-modifying, class 1 histone deacetylase (HDAC) inhibitor
hat alters gene transcription by catalyzing the removal of acetyl
roups from lysine residues in histones (Akilov and Geskin, 2011;
hot et al., 2013; ISTODAX®, 2014). HDAC treatment also leads to
e-acetylation of non-histone proteins, such as transcription fac-
ors (ISTODAX®, 2014). Romidepsin is indicated for the treatment
f CTCL in patients who have received at least one prior systemic
herapy (ISTODAX®, 2014). Another HDAC inhibitor, vorinostat, is
lso approved for use in previously treated CTCL. Vorinostat is an
rally bioavailable, pan-HDAC inhibitor licensed to treat cutaneous
anifestations in patients with CTCL who have progressive, persis-
ent, or recurrent disease on or following two systemic therapies
ZOLINZA®, 2013). The ﬁnal approved therapy is the CD25-directed,
V interleukin-2 (IL-2)—diphtheria toxin fusion protein, denileukin
iftitox, which is approved to treat patients with persistent or
ecurrent CTCL whose malignant cells express the CD25 compo-
ent of the IL-2 receptor (ONTAK®, 2011). Of these agents, only
exarotene is approved by the European Medicines Agency to treat
kin manifestations of advanced stage CTCL in adult patients refrac-
ory to at least one systemic treatment (Targretin®, 2014).
Oral bexarotene was shown to be effective in refrac-
ory/persistent CTCL in two phase 2/3 trials, both published in
001, which enrolled patients (diagnoses not speciﬁed) with early-
tage (N = 58) and advanced (N = 94) CTCL, respectively (Duvic et al.,
001a; Duvic et al., 2001b). Forty-ﬁve percent of patients with
dvanced CTCL who received the currently recommended starting
ose of 300 mg/m2/day (Targretin®, 2015) achieved an objective
esponse (median duration 9.8 months; clinical CR rate 2%); this
ompared with an ORR of 55% (median duration 12.6 months; clin-
cal CR rate 13%) in patients who received doses >300 mg/m2/day
Duvic et al., 2001a). These responses were accompanied by
mprovements in skin appearance, pruritus, and quality of life.
n early-stage patients, ORRs at bexarotene doses of 300 and
300 mg/m2/day were 54% (clinical CR rate 7%; median time to
rogression [TTP] 6.9 months) and 67% (clinical CR rate 27%;
edian TTP 16.9 months), respectively (Duvic et al., 2001b). As
hese responses are higher than in advanced disease, it appears
hat bexarotene may  be more active if given earlier on in the dis-
ase course, a premise that is supported by observational data
Sokolowska-Wojdylo et al., 2014; Väkevä et al., 2012). Signiﬁcant
ide effects reported during bexarotene therapy include hypothy-
oidism, altered lipid metabolism, and glucose and liver enzyme
bnormalities (Scarisbrick et al., 2013); in the main, these AEs can
e managed with careful monitoring and supportive treatments.
ther common bexarotene-associated toxicities include headache,
sthenia, skin rash, leukopenia, anemia, nausea/vomiting, infec-
ion, peripheral edema, abdominal/back pain, diarrhea, pruritus,
nd dry skin (Targretin®, 2015; Sokołowska-Wojdyło et al., 2013).
New data reporting on long-term experience with single-agent
exarotene suggests that durable responses are possible in pre-
reated CTCL patients (lasting for a median duration of 8–21 months
epending on the disease stage) providing that side effects are man-
ged proactively (Sokolowska-Wojdylo et al., 2014; Väkevä et al.,
012; Abbott et al., 2009). Bexarotene has also recently demon-
trated anti-lymphoma activity in rarer variants of CTCL, as well
s the more common diagnoses, in a large retrospective cohort
tudy of 200 patients with CTCL and ≥1 prior treatment failure
Weichenthal et al., 2013). ORRs in the different CTCL subtypes
ere as follows: MF  37%, CD30+ pcALCL 50%, LyP 60%, SS 33%, andogy/Hematology 99 (2016) 228–240
other rare CTCL forms 33%. Overall, these data indicate that oral
bexarotene should be considered as a key option for all subtypes
of relapsed/refractory CTCL, including rare variants. Interestingly,
combining or sequencing bexarotene with other treatments, such
as denileukin diftitox, gemcitabine, interferon-2b, or pralatrexate,
in relapsed/refractory CTCL appears to offer no major advantage, in
terms of response, over monotherapy with either agent (although
controlled trials are not available) (Foss et al., 2005; Illidge et al.,
2013; Straus et al., 2007; Talpur et al., 2014); the reasons for this
are not clear. Though not indicated, other oral retinoids (tretinoin
[all-trans-retinoic acid], isotretinoin, acitretin, and alitretinoin) are
also sometimes used to treat CTCL (National Cancer Institute, 2015;
Sokołowska-Wojdyło et al., 2013). These agents appear to have
some clinical activity, but evidence supporting their use is patchy
and prospective clinical trials are lacking (Sokołowska-Wojdyło
et al., 2013; Kapser et al., 2015; Cheeley et al., 2013).
The approval of romidepsin in CTCL was  based on the results of
two single-arm phase 2 trials, involving a total of 167 patients with
refractory CTCL, mainly MF  or SS (Piekarz et al., 2009; Whittaker
et al., 2010). Across the two  studies, both of which included highly
pretreated patients, romidepsin was  associated with ORRs of 34%
(in both studies; measured using stringent response criteria) and
CR rates of 6–7%; median duration of response was 14–15 months,
with some patients maintaining their response for >3 years. In
the larger of the two  trials, romidepsin was  associated with an
anti-pruritic effect, in which 43% of evaluable patients achieved
a clinically meaningful improvement in pruritus, including those
who did not achieve an objective response (Whittaker et al., 2010).
As also shown in PTCL (Khot et al., 2013; ISTODAX®, 2014), the most
frequently reported side effects with romidepsin are infections,
fatigue/asthenia, nausea, vomiting, and transient thrombocytope-
nia, neutropenia, and anemia (Foss et al., 2014); most of these AEs
tend to be of mild or moderate intensity. Infection represents the
most common serious AE and the most frequent cause of hospital-
ization (Foss et al., 2014).
The oral HDAC inhibitor, vorinostat, was associated with ORRs
of 24–30% in patients with refractory MF  or SS who were treated
in two key phase 2 trials (N = 33 and 74, respectively) (Olsen et al.,
2007; Duvic et al., 2007). CRs were rare (only one patient had a CR)
and median TTP was  <6 months in both studies, an observation that
may  be explained, at least in part, by the fact that many patients
had advanced disease and had received multiple lines of prior ther-
apy (Olsen et al., 2007; Duvic et al., 2007). More recent data suggest
that vorinostat can induce durable responses lasting for ≥2 years in
some patients (Duvic et al., 2009b; Kogge et al., 2015). AEs associ-
ated with vorinostat tend to be mild to moderate in intensity, and
treatment is usually well tolerated (Olsen et al., 2007; Duvic et al.,
2007). The most common drug-related AEs reported in the largest
of the two phase 2 trials were diarrhea, fatigue, nausea, anorexia,
dysgeusia, and thrombocytopenia (Olsen et al., 2007). Grade ≥3  AEs
were uncommon (≤5% incidence), although there was an increased
risk of thromboembolism (Olsen et al., 2007), which necessitates
monitoring during treatment (ZOLINZA®, 2013). While results are
not remarkable, the vorinostat and romidepsin data both support
HDAC inhibition as an important therapeutic strategy in CTCL,
not only for lymphoma control but also to alleviate bothersome
symptoms, such as pruritus, without increasing morbidity through
toxicity (Olsen et al., 2007; Duvic et al., 2007). Current combination
trials have been disappointing, but it is still likely that increased
beneﬁt will be achieved through combining HDAC inhibitors with
other interventions or treatment modalities.
A large number of clinical trials have explored the utility of
denileukin diftitox for the treatment of CD25+ relapsed/refractory
CTCL (LeMaistre et al., 1998; Saleh et al., 1998; Olsen et al., 2001;
Prince et al., 2010; Prince et al., 2013; Duvic et al., 2013a; Duvic et al.,
2013b). In a recently published pooled analysis of data from three
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hase 3 studies (N = 263), the ORR with denileukin diftitox was 38%
CR rate 9%) and median duration of response was  9.1 months,
ith some CTCL patients maintaining a response for >3.5 years
Duvic et al., 2013b). Patients who have been retreated follow-
ng prior exposure to denileukin diftitox also appear to beneﬁt,
nd can achieve similar response rates (28–40%) to those obtained
n ﬁrst use (Duvic et al., 2013a; Duvic et al., 2013b). In addition,
enileukin diftitox treatment is associated with improvements in
atient quality of life, skin appearance, and pruritus severity (Duvic
t al., 2002), and there is emerging evidence that even patients
ith CD25–CTCL may  derive some beneﬁt from treatment (Duvic
t al., 2013b). Across the three phase 3 trials, the most common AEs
ssociated with denileukin diftitox were nausea, pyrexia, fatigue,
apillary leak syndrome, and rigors (Duvic et al., 2013b). Unfor-
unately, because denileukin diftitox is linked with a number of
erious side effects, including capillary leak syndrome, infusion
eactions, and loss of visual acuity (ONTAK, 2011), production of
he current formulation was discontinued by the manufacturer in
anuary 2014. A phase 3 trial of E7777 – a formulation of denileukin
iftitox with improved purity and a higher percentage of active
rotein monomer species – is, however, now ongoing in patients
ith persistent/recurrent CD25+ CTCL (MF  or SS) (NCT01871727)
Duvic et al., 2014b). For this trial to be successful, efﬁcacy will
ave to be maintained with a much reduced risk of serious adverse
eactions. Early results from the dose-ﬁnding, lead-in phase for this
tudy indicate that the toxicity proﬁle of E7777 is acceptable and, to
ate, no new safety signals relative to the parent compound have
een identiﬁed (although two patients have developed capillary
eak syndrome) (Duvic et al., 2014b). Five of the 17 patients (13
ith MF  and 4 with SS) treated so far have achieved an objective
esponse and dose-ﬁnding is continuing.
.3. Investigational and off-label therapies in relapsed/refractory
TCL
As in PTCL, various novel therapeutic agents and regimens are
urrently under investigation in relapsed/refractory CTCL (usually
F  or SS). These treatments include novel chemotherapies (prala-
rexate and forodesine), immunomodulatory drugs (lenalidomide),
ext-generation HDAC inhibitors (belinostat and panobinostat),
ther targeted agents (bortezomib and duvelisib), and biolog-
cs (brentuximab vedotin, alemtuzumab, mogamulizumab, and
-dmDT390-bisFv(UCHT1)). Available data on the efﬁcacy of these
xperimental drugs are presented in Table 1.
Novel chemotherapeutic agents that are in clinical trials
n previously treated CTCL include pralatrexate (a potent IV
ntifolate, 10-deazaaminopterin analog of methotrexate, currently
ndicated in relapsed or refractory PTCL, which acts to disrupt
NA/RNA synthesis through inhibition of dihydrofolate reductase
nd thymidylate synthase (Wang et al., 2003; Sirotnak et al., 1998;
himanovsky and Dasanu, 2013; FOLOTYN®, 2012) and forode-
ine (a potent, transition-state, purine nucleoside phophorylase
nhibitor that works to disrupt DNA synthesis through accu-
ulation of plasma 2′-deoxyguanosine and intracellular dGuo
riphosphate, and consequent inhibition of ribonucleotide reduc-
ase [Gandhi and Balakrishnan, 2007; Korycka et al., 2007]).
ollowing demonstration of activity in PTCL (O’Connor et al., 2011),
ralatrexate has exhibited favorable single-agent anti-lymphoma
ffects (ORR of 41% [45% at the recommended dose] and a CR rate
f 6%, including some long-lasting responses) in a small phase
/2 trial of patients with heavily pretreated, relapsed/refractory
TCL, mainly MF  or SS (Horwitz et al., 2012). Tolerability was gen-
rally acceptable and severe AEs, with the exception of grade 3
ral mucositis (15%), were uncommon. As in PTCL (O’Connor et al.,
011), the most frequently reported AEs were mucositis, fatigue,ogy/Hematology 99 (2016) 228–240 235
nausea/vomiting, and skin toxicity (Horwitz et al., 2012). Hemato-
logic toxicities were also observed.
Promising results (ORRs of 27–54%) were reported for forode-
sine in early studies in CTCL (Duvic et al., 2006b; Duvic et al., 2009a),
but ﬁnal results from a large multicenter, phase 2 trial suggest that
forodesine may  only have partial activity in relapsed or refractory
MF or SS (ORR of 11% with no CRs, and a median TTP of 6.3 months)
(Dummer et al., 2014). It should be noted, though, that some
patients did achieve durable responses and, as all patients in this
phase 2 study had failed ≥3 prior systemic therapies, it could be that
forodesine may  be more effective in less treatment-experienced
patients. The study investigators also suggested that the patients
had been under-dosed (Dummer et al., 2014). AEs reported with
forodesine included peripheral edema, fatigue, insomnia, pruritus,
diarrhea, headache, and nausea (Dummer et al., 2014). Of  concern,
some patients treated with forodesine developed serious infec-
tions leading to death (Dummer et al., 2014), and therefore close
monitoring for infectious episodes will be required in any future
investigations of this drug.
The oral thalidomide analog, lenalidomide – an immunomodu-
latory drug with antiangiogenic and antineoplastic properties that
is currently used in multiple myeloma and mantle cell lymphoma
(REVLIMID®, 2014; National Cancer Institute, 2016) – achieved
an ORR of 28%, a median progression-free survival (PFS) of 8
months, and a median overall survival of 43 months when given
as monotherapy to 32 patients with heavily pretreated, advanced
MF or SS (Querfeld et al., 2014). However, high toxicity (e.g., anemia,
fatigue/malaise, skin pain/burning, pruritus, diarrhea, infection,
and lower leg edema) resulted in two-ﬁfths of patients (41%) dis-
continuing the study (Querfeld et al., 2014). These results suggest
that a lower dose of lenalidomide or schedule modiﬁcation is likely
to be required, along with supportive measures, if the drug is to be
investigated further in refractory CTCL.
Based on experience with romidepsin and vorinostat, the
hydroxamic acid-type IV pan-HDAC inhibitor, belinostat (O’Connor
et al., 2011; BELEODAQ®, 2014), which is approved for the treat-
ment of patients with relapsed or refractory PTCL (BELEODAQ®,
2014), and the oral pan-HDAC inhibitor, panobinostat, which is
approved for use in previously treated multiple myeloma (National
Cancer Institute, 2016), have both been investigated in phase 2 tri-
als of patients with relapsed/refractory CTCL (predominantly MF
or SS) (Foss et al., 2015; Duvic et al., 2013c). While belinostat
and panobinostat have predictable and manageable safety proﬁles
typical of HDAC inhibitors (predominantly mild or moderate gas-
trointestinal, constitutional, and hematologic [panobinostat only]
AEs, and altered laboratory parameters), response rates have been
modest (<20%) and CRs relatively rare (Foss et al., 2015; Duvic
et al., 2013c). Nonetheless, some patients did achieve prolonged
responses and the ORRs were not dissimilar to those seen with
vorinostat (Olsen et al., 2007; Duvic et al., 2007); the observed lack
of activity may  simply reﬂect the extensive treatment histories of
patients included in the trials. It would now be interesting to see
how these two drugs compare with vorinostat and romidepsin but,
at present, no studies are planned.
The ﬁrst-generation 20S proteosome inhibitor, bortezomib, an
IV drug indicated for use in multiple myeloma and pretreated
mantle cell lymphoma (National Cancer Institute, 2015; National
Cancer Institute, 2015), has been investigated in a small phase 2
trial of 12 assessable patients with relapsed/refractory CTCL, pre-
dominantly MF  (Zinzani et al., 2007). Treatment with single-agent
bortezomib was  associated with an ORR of 67% and a CR rate of 17%,
with all patients remaining in remission for 7–14+ months. Borte-
zomib was also generally well tolerated and no grade 4 toxicities
were observed. In spite of these promising initial results, no further
development of bortezomib speciﬁcally in CTCL has been reported,
although the combination of bortezomib and romidepsin is under
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nvestigation in a phase 1 trial of patients with various forms of
elapsed/refractory NHL, including one patient with CTCL (Holkova
t al., 2014). In this trial, the single CTCL patient achieved a best
esponse of stable disease to bortezomib/romidepsin.
Another drug to be investigated in relapsed/refractory CTCL
s the anti-CD30 antibody-drug conjugate, brentuximab vedotin,
hich comprises an anti-CD30 antibody (cAC10) linked to the
otent microtubule-disrupting agent, monomethyl auristatin E
MMAE) (Chen et al., 2013). Brentuximab vedotin targets CD30+
alignant T cells by binding to CD30, becoming internalized, and
hen releasing MMAE  to provoke cell cycle arrest and programmed
ell death (Chen et al., 2013). Brentuximab vedotin has shown high
ctivity (ORR of 73%, CR rate of 35%, and median PFS of 1.1 year)
n a phase 2 trial of 48 patients with CD30+ relapsed/refractory
TCLs and LyP (Duvic et al., 2015a). The drug was active in MF
ORR 54%) irrespective of the degree of CD30 expression, and
chieved an ORR of 100% in the small number of patients with
D30+ pcALCL and/or LyP (n = 12) (Duvic et al., 2015a). Signiﬁ-
antly, responses were observed in patients with multifocal lesions
nd in those with regional lymph node involvement. Toxicities,
hich included peripheral neuropathy, drug rashes, diarrhea, nau-
ea, fatigue, myalgias, localized skin infections, and neutropenia,
ere as expected from experience in other indications (Duvic et al.,
015a; Chen et al., 2013; Pro et al., 2012; ADCETRIS®, 2015a;
DCETRIS®, 2015b). A separate investigator-initiated phase 2 trial
f 32 patients with previously treated MF  or SS (91% with large-
ell transformation or folliculotropism) across all CD30 expression
evels reported an ORR of 70% (including one global CR) (Kim et al.,
015). Responses were seen across all levels of CD30 expression,
ut the probability of achieving a response was lower in patients
ith CD30 levels of <5% (p < 0.005). At 12 months, 79% of responses
ere still ongoing and 54% of responders were progression-free.
dditionally, eight patients had a >90% reduction in their Modiﬁed
everity Weighted Assessment Tool (mSWAT) score. These excit-
ng results have led to the initiation of a phase 3 trial investigating
he efﬁcacy and safety of brentuximab vedotin versus physician’s
hoice (methotrexate or bexarotene) in previously treated patients
ith CD30+ primary CTCL (MF  or pcALCL) (NCT01578499). First
esults are expected to be reported in the near future.
The humanized, anti-CD52 monoclonal antibody, alemtuzumab
 a drug currently indicated for use in B-cell chronic lymphocytic
eukemia that targets the CD52 antigen expressed on malignant
 cells (and other immune cells) to enable antibody-dependent
ellular-mediated lysis (Campath®, 2014) – has also been inves-
igated in pretreated cutaneous T-cell malignancies. Alemtuzumab
as been shown to be active in relapsed/refractory CTCL (with ORRs
anging from 38 to 86%), including advanced erythrodermic MF/SS
ORR 84%, CR rate 47%) (Kennedy et al., 2003; Lundin et al., 2003;
inzani et al., 2005; Bernengo et al., 2007; Querfeld et al., 2009), and
here is some evidence to suggest that alemtuzumab may  be more
ffective in SS than MF  (Bernengo et al., 2007; Querfeld et al., 2009).
dditionally, long-lasting responses have been reported in a minor-
ty of patients (Kennedy et al., 2003; Lundin et al., 2003; Zinzani
t al., 2005; Bernengo et al., 2007; Querfeld et al., 2009). However,
reatment with alemtuzumab can result in serious opportunistic
nfections as a consequence of immunosuppression (Kennedy et al.,
003; Lundin et al., 2003; Campath®, 2014; Zinzani et al., 2012) and,
s such, the drug must be used carefully along with antimicrobials
nd at lower doses to reduce the likelihood of infections. Unfortu-
ately, this elevated risk of infection, combined with the increased
isk of infusion reactions and cytopenias (Campath®, 2014), has
esulted in the commercial withdrawal of alemtuzumab in the
nited States, and the drug is now only available through the Cam-
ath Distribution Program or via clinical trials. Further dedicated
linical development of alemtuzumab in CTCL is unlikely.ogy/Hematology 99 (2016) 228–240
Another antibody to be investigated in CTCL is the defucosy-
lated, humanized anti-CC chemokine receptor 4 (CCR4) monoclonal
antibody, mogamulizumab (KY-0761), which targets the CCR4 anti-
gen expressed on type 2 helper T cells or regulatory T (Treg) cells
(Ogura et al., 2014). As the CCR4 antigen is variably expressed on
neoplastic CTCL cells (Ni et al., 2015; Yagi et al., 2006; Yamaguchi
et al., 2006), there is a rationale for clinical study in this setting.
Anti-lymphoma activity has been observed with mogamulizumab
in patients with relapsed CCR4+ CTCL (ORR 38%, CR rate 14%), and
in patients with previously treated MF  or SS (ORR 37% [47% in
SS patients and 29% in MF  patients]) (Ogura et al., 2014; Duvic
et al., 2015b). Signiﬁcantly, mogamulizumab appears to lack many
of the serious autoimmune-associated side effects associated with
alemtuzumab; the most common AEs, which are largely low grade,
reversible and manageable, include hematologic toxicities, pyrexia,
skin disorders, nausea, chills, headache, and infusion-related reac-
tions (Ogura et al., 2014). Based on these data and the promising
results in PTCL (Ogura et al., 2014; Duvic et al., 2015b; Ishida
et al., 2012; Yamamoto et al., 2010), mogamulizumab is currently
being investigated versus vorinostat in a pivotal phase 3 trial in
relapsed/refractory CTCL (NCT01728805) (Kim et al., 2014). The
primary data from this study are expected to be released in mid-
2016.
A-dmDT390-bisFv(UCHT1) is a high potency, experimental
fusion protein immunotoxin (comprising catalytic and transloca-
tion domains of diphtheria toxin fused to two anti-human CD3 Fv
fragments) that is targeted against the CD3 receptor, commonly
expressed on skin-tropic T cells (Frankel et al., 2013; Woo  et al.,
2008). Data from the phase 1 portion of a phase 1/2 trial revealed
an ORR of 35% among 17 evaluable patients with CTCL (most of
whom had failed 1–4 prior therapies), including four CRs, three of
which were >4 years’ duration (Frankel et al., 2013). A subanalysis
showed an ORR of 86% and CR rate of 56% in patients with stage
IB/IIB disease and a skin coverage mSWAT  score of <50%. As the CRs
in this patient subset were long-lasting, these results suggest the
potential for clinical cure in these selected patients (Frankel et al.,
2013). The phase 2 portion of this trial is now enrolling patients who
have characteristics associated with the high treatment response
rate (NCT00611208). Side effects reported so far, most of which
were mild or moderate and transient (following implementation
of supportive therapies), include fevers, chills, nausea, transami-
nasemia, hypoalbuminemia, lymphopenia, viral reactivation, and
hypophosphatemia (Frankel et al., 2013).
Lastly, the oral phosphoinositide-3-kinase-, inhibitor,
duvelisib (IPI-145), has entered clinical trials in TCL (Horwitz
et al., 2014). Phosphoinositide-3-kinase- and  are intracellular
signaling molecules believed to play important roles in facilitating
the growth and survival of T-cell malignancies, including CTCL
(Horwitz et al., 2014; Curran and Smith, 2014; Winkler et al., 2013).
Data from a disease-speciﬁc cohort of patients with relapsed or
refractory CTCL or PTCL in an ongoing phase 1 study showed
that duvelisib could achieve an ORR of 38% (all partial responses)
in 16 evaluable CTCL patients (Horwitz et al., 2014). The most
common grade ≥3 AEs among all patients combined were elevated
liver transaminases, rash, and neutropenia, and approximately
one-third of patients discontinued due to AEs. Based on these
preliminary results, further evaluation of this novel oral agent in
relapsed/refractory CTCL is warranted.
4. Concluding remarksThis paper presents a comprehensive report on the current
and future potential treatment options for relapsed and/or refrac-
tory CTCLs, particularly MF  and SS. The initial treatment strategies
for CTCLs differ considerably from those used for PTCLs (National
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ancer Institute, 2015; Dreyling et al., 2013; Willemze et al., 2013),
et there is a large overlap in the systemic options used to man-
ge relapsed/refractory disease. Targeted agents, such as the HDAC
nhibitors, are becoming important options for relapsed/refractory
TCL patients when other approaches have failed, and add to
he available treatment armamentarium, which includes the oral
etinoid, bexarotene, and conventional chemotherapies. Novel
nvestigational therapies, particularly biologic agents, are also
howing great promise. With their differential activity in different
ubsets of patients, biologic agents may  offer the potential for per-
onalized therapy. It is hoped that over the next 2–3 years, ongoing
hase 3 trials (e.g., mogamulizumab in CTCL, E777 in CD25+ MF/SS,
nd brentuximab vedotin in CD30+ MF  or pcALCL) will yield pos-
tive results, and thereby boost the range of options available to
reat this diverse range of refractory malignancies.
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